Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a, CD73, dual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback